ARTICLE | Company News

Amgen, Isis antisense deal

December 13, 2001 8:00 AM UTC

AMGN and ISIP will develop antisense therapeutics using ISIP's 2'-O-methoxyethyl second-generation chemistry to inhibit multiple gene targets. Under the 3-year deal, AMGN has the right to develop and market resulting products. ISIP will be eligible for milestones and royalties. ISIP was up $2.84 (15%) to $21.99, while AMGN was off $4.20 to $60.19 on Wednesday. ...